Screener
Pulse Biosciences, Inc. PLSE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Pulse Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Pulse Biosciences, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:23 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-026288
FAQ
- What is Pulse Biosciences, Inc.'s cash & equivalents?
- Pulse Biosciences, Inc. (PLSE) reported cash & equivalents of $101.62M in Q2 2026.
- How has Pulse Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Pulse Biosciences, Inc.'s cash & equivalents decreased by 4.4% year-over-year, from $106.35M to $101.62M.
- What is the long-term trend for Pulse Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Pulse Biosciences, Inc.'s cash & equivalents has grown at a 45.3% compound annual growth rate (CAGR), from $12.46M to $80.74M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Pulse Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude